ADVERTISEMENTREMOVE AD
Members Only
lock close icon

Hostility Towards Agri-Biotech MNCs, But What About Our Faults?

While private firms in the field of GM technology bid farewell to India, govt fails to encourage the public sector.

Updated: 
story-hero-img
i
Aa
Aa
Small
Aa
Medium
Aa
Large

A wave of consolidation has hit agribusinesses following the global downturn in commodity prices. Companies are trying to ride the current lean patch by cutting costs and combining strengths. Dow Chemicals and DuPont have merged, ChinaChem has acquired Syngenta, Monsanto was said to be talking to BASF for a merger of their agrichemicals businesses; now Bayer is making a bid for it.

Some might find the accumulation of corporate power troubling. So long as the giants face competitive pressure, size should not be a matter of concern. Indeed, it allows them to deploy enormous funds for research. Bayer has announced, it will spend 2.5 billion euros ($2.82 billion) to create infrastructure for innovation over the next three years. This excludes 1 billion euros ($1.13 billion) it will spend annually on R&D. Last year’s entire budget of the Department of Agricultural Research and Extension (DARE) was less than $850 million.

Also read: Why Giving GM Mustard a Chance is Reminiscent of the Nazi Era

Published: 
Become a Member to unlock
  • Access to all paywalled content on site
  • Ad-free experience across The Quint
  • Listen to paywalled content
  • Early previews of our Special Projects
×
×